Loading
A phase 2 trial of Mifepristone and Paclitaxel / nab-paclitaxel in Breast cancer, run by University of Chicago, active and no longer recruiting.
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT02788981 by University of Chicago, with 29 participants planned, started 2017-03-28 and due to reach its primary completion in 2022-12-21. Interventions recorded: Mifepristone, Placebo, Nab-Paclitaxel. Conditions recorded: Breast Cancer.
Linked to the drug Mifepristone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
29 enrolled.
95% CI 1.0 to 5.0; Figures from the ClinicalTrials.gov results section (first posted 2024-02-16), not from a publication · 95% CI 1.0 to 6.0
Source95% CI 6.0 to 28.0; Figures from the ClinicalTrials.gov results section (first posted 2024-02-16), not from a publication · 95% CI 2.0 to 15.0
SourceShares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.